journal
https://read.qxmd.com/read/38609728/post-transplant-lymphoproliferative-disease-of-two-different-histological-types
#1
LETTER
Takashi Onaka, Koichi Ohshima, Izumi Kinoshita, Naoto Miyakawa, Atsuto Shirae, Aiko Kato-Ogura, Yasuyuki Otsuka, Fumie Iwai, Akihito Yonezawa
No abstract text is available yet for this article.
April 13, 2024: Annals of Hematology
https://read.qxmd.com/read/38609727/therapeutic-progress-in-relapsed-refractory-multiple-myeloma
#2
REVIEW
Qi Chen, Min Zhang, Shan Zheng, Yuxin Tong, Yamin Tan
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction regimen based on immunomodulatory drugs and proteasome inhibitors combined with autologous stem cell transplantation. However, MM remains incurable; therefore, therapies for relapsed/refractory MM (RRMM) are emerging and evolving rapidly. This study aimed to summarize and review the results of RRMM trials over the past 5 years to provide a holistic overview and insights for practitioners in related fields and to provide additional ideas for clinical trialists...
April 13, 2024: Annals of Hematology
https://read.qxmd.com/read/38609726/impact-of-minimal-residual-disease-response-and-of-status-of-disease-on-survival-after-blinatumomab-in-b-cell-acute-lymphoblastic-leukemia-results-from-a-real-life-study
#3
JOURNAL ARTICLE
Salvatore Leotta, Uros Markovic, Andrea Duminuco, Antonino Mulè, Ferdinando Porretto, Vincenzo Federico, Massimo Gentile, Domenico Pastore, Luca Lo Nigro, Carmine Selleri, Bianca Serio, Valeria Calafiore, Caterina Patti, Elisa Mauro, Calogero Vetro, Cinzia Maugeri, Marina Parisi, Paolo Fiumara, Laura Parrinello, Sara Marino, Grazia Scuderi, Bruno Garibaldi, Maurizio Musso, Nicola Di Renzo, Ernesto Vigna, Enrica Antonia Martino, Francesco Di Raimondo, Giuseppe Milone
Blinatumomab is a bispecific T-cell engager approved for relapsed/refractory and minimal residual disease positive B-cell Acute Lymphoblastic Leukemia. We conducted a retrospective study evaluating the outcome of Blinatumomab. The impact of clinical and treatment-related variables on cumulative incidence of relapse/progression (CIRP), event-free (EFS) and overall survival (OS) was analyzed. From January 2016 to December 2022 50 Ph'- (37) and Ph+ (13) B-ALL patients received Blinatumomab. The median age was 37...
April 13, 2024: Annals of Hematology
https://read.qxmd.com/read/38609725/cerebral-infarction-in-a-patient-with-inhibitor-positive-hemophilia-b-treated-with-plasma-derived-factor-viia-and-factor-x-mixture
#4
LETTER
Katsuyoshi Shimozawa, Hiroshi Yagasaki, Koji Kanezawa, Ichiro Morioka
No abstract text is available yet for this article.
April 13, 2024: Annals of Hematology
https://read.qxmd.com/read/38607553/loss-of-nlrp6-expression-increases-the-severity-of-intestinal-injury-after-syngeneic-hematopoietic-stem%C3%A2-cell-transplantation
#5
JOURNAL ARTICLE
Shengyun Zhu, Xue Zhang, Kairen Xu, Jing Liang, Weiwei Wang, Lingyu Zeng, Kailin Xu
NLRP6 plays a crucial role in maintaining intestinal homeostasis by regulating the interaction between the intestinal mucosa and the microbiota. However, the impact of NLRP6 deficiency on intestinal damage following hematopoietic stem cell transplantation (HSCT) remains poorly understood. In this study, we established a syngeneic HSCT mouse model using C57BL/6 mice as donors and NLRP6-/- or C57BL/6 mice as recipients. Our findings revealed that NLRP6 deficiency had minimal influence on peripheral blood cell counts and splenic immune cell proportions in transplanted mice...
April 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38605231/upfront-allogeneic-hematopoietic-stem-cell-transplantation-for-adult-t-cell-acute-lymphoblastic-leukemia-lymphoma-in-first-complete-remission-a-single-center-study
#6
JOURNAL ARTICLE
Zhenyang Gu, Fei Li, Meng Li, Lu Wang, Ning Lu, Xiangshu Jin, Lili Wang, Chunji Gao, Liping Dou, Daihong Liu
BACKGROUND: Real-world data on outcomes of upfront allogeneic hematopoietic stem cell transplantation (allo-HCT) for adult T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patients in first complete remission (CR1) is still lacking. METHODS: A single center retrospective study was conducted from 94 consecutive patients received their first allo-HCT between 2010 and 2021, which include 76 patients received upfront allo-HCT and 18 patients received allo-HCT in non-upfront settings...
April 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38594416/comparable-outcomes-of-allogeneic-peripheral-blood-versus-bone-marrow-hematopoietic-stem-cell-transplantation-from-a-sibling-donor-for-pediatric-patients
#7
JOURNAL ARTICLE
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyery Kim, Hyun Jin Park, Hyoung Jin Kang
Traditionally, bone marrow (BM) has been preferred as a source of stem cells (SCs) in pediatric hematopoietic SC transplantation (HSCT); however, the use of peripheral blood SCs (PBSC) has recently increased. With advancing graft-versus-host disease (GVHD) prophylaxis, whether the BM is still a better SC source than PB in sibling donor HSCT remains controversial. Here, we compared the results of BM transplantation (BMT) and PBSC transplantation (PBSCT) in pediatric patients with malignant or non-malignant diseases receiving sibling HSCT using a total of 7...
April 10, 2024: Annals of Hematology
https://read.qxmd.com/read/38592500/bibliometric-analysis-of-worldwide-research-on-polycythemia-vera-in-the-21st-century
#8
REVIEW
Zhengjiu Cui, Fei Luo, Yuan Zhang, Juanjuan Diao, Yueli Pan
Polycythemia vera (PV) is a myeloproliferative tumor with low incidence and complex symptoms, affecting patients' quality of life and shortening their life span. Since the beginning of the 21st century, there has been an update but a need for uniform consensus regarding diagnosing and treating PV. With the continued interest of researchers in this field, a bibliometric study of PV is necessary. This paper aims to analyze articles on PV through bibliometric software to provide collaborative information and new ideas for researchers in this field...
April 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38589717/could-it-be-vexas
#9
JOURNAL ARTICLE
Hippolyte Guerineau, Milena Kohn, Antoine Al Hamoud, Jacques Sellier, Jennifer Osman, Aurélie Cabannes-Hamy
We report the case of the youngest patient described with VEXAS syndrome associated with MDS-IB1, successfully treated with azacitidine-venetoclax and allogeneic stem cell transplant.
April 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38584216/thiotepa-busulfan-fludarabine-based-conditioning-as-a-promising-approach-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-blastic-plasmacytoid-dendritic-cell-neoplasm
#10
JOURNAL ARTICLE
Xianbo Huang, Shasha Wang, Yu Xu, Chen Mei, Qingmei Han, Xianhui Wu, Fengwei Du, Yanling Ren, Jie Jin, Hongyan Tong, Jiejing Qian
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive myeloid malignancy associated with a poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) has emerged as a potential treatment strategy for BPDCN, standardized conditioning regimens remain lacking. In this manuscript, we present two cases of BPDCN that were treated with a thiotepa-busulfan-fludarabine (TBF)-based conditioning regimen prior to allo-HSCT. Both cases demonstrated complete remission post-transplantation, sustained donor chimerism, and remission maintenance, suggesting the potential efficacy of the TBF conditioning regimen for BPDCN transplantation...
April 8, 2024: Annals of Hematology
https://read.qxmd.com/read/38581547/impact-of-genotype-on-multi-organ-iron-and-complications-in-patients-with-non-transfusion-dependent-%C3%AE-thalassemia-intermedia
#11
JOURNAL ARTICLE
Antonella Meloni, Laura Pistoia, Paolo Ricchi, Sergio Bagnato, Filomena Longo, Giuseppe Messina, Sabrina Bagnato, Vincenza Rossi, Stefania Renne, Riccardo Righi, Priscilla Fina, Vincenzo Positano, Filippo Cademartiri
We evaluated the impact of the genotype on clinical and hematochemical features, hepatic and cardiac iron levels, and endocrine, hepatic, and cardiovascular complications in non-transfusion-dependent (NTD) β-thalassemia intermedia (TI) patients. Sixty patients (39.09 ± 11.11 years, 29 females) consecutively enrolled in the Myocardial Iron Overload in Thalassemia project underwent Magnetic Resonance Imaging to quantify iron overload, biventricular function parameters, and atrial areas and to detect replacement myocardial fibrosis...
April 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38581546/efficacy-and-prognostic-factors-of-allogeneic-hematopoietic-stem-cell-transplantation-treatment-for-adolescent-and-adult-tlymphoblastic-leukemia-lymphoma-a-large-cohort-multicenter-study-in-china
#12
JOURNAL ARTICLE
Lan Luo, Yang Jiao, Yan Li, Ping Yang, Jinjie Gao, Sai Huang, Wenyang Huang, Jijun Wang, Fei Dong, Xiaoyan Ke, Dehui Zou, Chunji Gao, Hongmei Jing
T lymphoblastic leukemia /lymphoma (T-ALL/LBL) is a rare and highly aggressive neoplasm of lymphoblasts. We evaluated 195 T-ALL/LBL adolescent and adult patients who received ALL-type chemotherapy alone (chemo,n = 72) or in combination with autologous hematopoietic stem cell transplantation(auto-HSCT,n = 23) or allogeneic hematopoietic stem cell transplantation(allo-HSCT,n = 100) from January 2006 to September 2020 in three Chinese medical centers. 167 (85.6%) patients achieved overall response (ORR) with 138 complete response (CR) patients (70...
April 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38578507/quality-of-life-after-immune-suppressive-therapy-in-aplastic-anemia
#13
JOURNAL ARTICLE
Iris N Lommerse, Chris Hinnen, Liesbeth M van Vliet, Beke Schubert, Jens Panse, Constantijn J M Halkes, Jennifer M-L Tjon
Acquired aplastic anemia (AA) is a rare form of immune-mediated bone marrow failure, which can result in life-threatening infections or bleeding if left untreated. Treatment consists of either immune suppressive therapy (IST) or allogeneic stem cell transplantation (alloHSCT). While considerable research has been published regarding survival, response rate and toxicity of both treatments, knowledge on the impact on quality of life (QoL) is scarce. We used the recently developed AA-specific QoL questionnaire (QLQ-AA/PNH-54) to evaluate QoL in a single center cohort of AA patients who were successfully treated with IST...
April 5, 2024: Annals of Hematology
https://read.qxmd.com/read/38568261/development-of-disseminated-intravascular-coagulation-in-asymptomatic-leukemic-non-nodal-mantle-cell-lymphoma
#14
JOURNAL ARTICLE
Takumi Kondo, Keito Ohara, Shohei Yoshida, Kensuke Kojima
No abstract text is available yet for this article.
April 3, 2024: Annals of Hematology
https://read.qxmd.com/read/38568260/hepatotoxicity-as-dose-limiting-toxicity-of-the-combination-of-bosutinib-and-atezolizumab-in-patients-with-chronic-myeloid-leukemia-results-of-the-zerolmc-study
#15
JOURNAL ARTICLE
Lucía Pérez-Lamas, Raquel de Paz Arias, Rosa Mª Ayala Díaz, Luis Felipe Casado Montero, Ángel Ramírez Payer, Magdalena Sierra, Francisca Ferrer Marín, Raúl Pérez López, Blanca Xicoy Cirici, Juan Luis Steegmann, María Teresa Gómez Casares, Joaquín Martínez-López, Valentín García-Gutiérrez
In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML...
April 3, 2024: Annals of Hematology
https://read.qxmd.com/read/38558184/the-role-of-therapeutic-plasma-exchange-in-plasma-cell-disorders
#16
REVIEW
Danai Dima, Jack Khouri
Therapeutic plasma exchange (TPE) is an extracorporeal technique where patient's plasma containing pathogenic substances is separated and removed from the whole blood, while the cellular component is returned to the patient mixed with replacement solution via an apheresis machine. Due to its ability to remove pathogenic substances from plasma including immunoglobulins, TPE has proven efficacious in the management of various disorders across different medical disciplines, including plasma cell dyscrasias, which are characterized by the abundant secretion of non-functional immunoglobulins produced by an abnormally proliferating plasma cell clone...
April 1, 2024: Annals of Hematology
https://read.qxmd.com/read/38556531/gilteritinib-combined-with-venetoclax-and-azacitidine-for-relapsed-acute-myeloid-leukemia-cocurrent-with-pure-red-cell-aplasia-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#17
JOURNAL ARTICLE
Jiawen Wang, Han Zhu, Kourong Miao
Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA occurring after ABO-matched allo-HSCT in a refractory/relapsed acute myeloid leukemia (R/R AML) patient. In this case, the patient received a combination treatment of Gilteritinib, Venetoclax, and Azacitidine. Remarkably, this treatment not only reduced myeloblasts but also facilitated the restoration of erythroid hematopoiesis...
April 1, 2024: Annals of Hematology
https://read.qxmd.com/read/38538977/comparison-of-rabbit-atlg-and-atg-for-gvhd-prophylaxis-in-hematological-malignancies-with-haploidentical-hematopoietic-stem-cell-transplantation
#18
JOURNAL ARTICLE
Zhengqin Tian, Qihang Man, Yixin Yang, Hexian Guan, Ying Wang, Rongmu Luo, Jingbo Wang
Rabbit anti-human T lymphocyte globulin (ATLG) and anti-thymocyte globulin (ATG) are commonly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). Yet, their efficacy and safety have seldom been compared in hematological malignancies with haploidentical HSCT. A retrospective analysis with 28 ATLG (total dosage, 20-30 mg/kg) and 18 ATG (total dosage, 8-10 mg/kg) patients were performed. The cumulative incidences of chronic GVHD and relapse were comparable between both groups...
March 28, 2024: Annals of Hematology
https://read.qxmd.com/read/38538976/palliative-care-for-patients-with-hematologic-malignancies-in-germany-a-nationwide-survey-on-everyday-practice-and-influencing-factors-from-the-perspective-of-treating-physicians
#19
JOURNAL ARTICLE
Cordula Gebel, Isabel Kruschel, Steffi Bodinger, Steffen T Simon, Dennis A Eichenauer, Anne Pralong, Ulrich Wedding
Integrating palliative care into the treatment of patients with advanced hematological malignancies (HM) remains challenging. To explore treating physicians' perspectives on current palliative care practice and to evaluate factors influencing integration, we conducted a nationwide online survey. Based on literature and expert review, the survey addressed the importance of palliative care, communication about life-threatening conditions, challenges in establishing goals of care, and factors influencing the integration of palliative care...
March 28, 2024: Annals of Hematology
https://read.qxmd.com/read/38538975/novel-methyltransferase-g9a-inhibitor-induces-ferroptosis-in-multiple-myeloma-through-nrf2-ho-1-pathway
#20
JOURNAL ARTICLE
Yu Zhang, Xiaoshun Wang, Xiaoqi Li, Xingfang Xiong, Renyu Xue, Lanlan Zang, Zhiqiang Wang, Lijuan Wang
Multiple myeloma (MM) is a common malignant hematologic neoplasm, and the involvement of epigenetic modifications in its development and drug resistance has received widespread attention. Ferroptosis, a new ferroptosis-dependent programmed death mode, is closely associated with the development of MM. The novel methyltransferase inhibitor DCG066 has higher cell activity, but its mechanism of action in MM has not been clarified. Here, we found that DCG066 (5µM) inhibited the proliferation and induced ferroptosis in MM cells; the intracellular levels of ROS, iron, and MDA were significantly elevated, and the level of GSH was reduced after the treatment of DCG066; The protein expression levels of SLC7A11, GPX4, Nrf2 and HO-1 were significantly reduced, and these phenomena could be reversed by ferroptosis inhibitor Ferrostatin-1 (Fer-1) and Nrf2 activator Tert-butyl hydroquinone (TBHQ)...
March 27, 2024: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.